(Q37781671)

23 August 2017

title

Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results (English)

1 reference

23 August 2017

Focus on renin–angiotensin system modulation and atrial fibrillation control after GISSI AF results (English)

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

20 June 2024

0 references

Ornella Durin

1

1 reference

23 August 2017

Claudio Pedrinazzi

2

1 reference

23 August 2017

Giuseppe Inama

3

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20729747

20 June 2024

publication date

1 December 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/01244665-201012000-00006

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Journal of Cardiovascular Medicine

20 June 2024

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

912-918

1 reference

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

20 June 2024

2

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Electrophysiologic mechanisms of perpetuation of atrial fibrillation

20 June 2024

3

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents

20 June 2024

4

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways

20 June 2024

5

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation

20 June 2024

6

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

20 June 2024

7

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

20 June 2024

8

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure

20 June 2024

9

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction

20 June 2024

10

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

20 June 2024

11

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction

20 June 2024

12

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program

20 June 2024

13

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

20 June 2024

14

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

20 June 2024

15

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

20 June 2024

16

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

20 June 2024

17

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

20 June 2024

18

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study

20 June 2024

19

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Losartan and prevention of atrial fibrillation recurrence in hypertensive patients

20 June 2024

20

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation

20 June 2024

21

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

20 June 2024

22

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

20 June 2024

23

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data

20 June 2024

24

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

20 June 2024

25

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation

20 June 2024

27

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation

20 June 2024

28

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence

20 June 2024

29

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.

20 June 2024

30

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

20 June 2024

31

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Effects of lisinopril in patients with heart failure and chronic atrial fibrillation

20 June 2024

32

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation

20 June 2024

33

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

The impact of suppressing the renin-angiotensin system on atrial fibrillation

20 June 2024

34

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis

20 June 2024

35

1 reference

https://api.crossref.org/works/10.2459/JCM.0B013E32833CDD6F

20 June 2024

Identifiers

1 reference

23 August 2017

1 reference